home / stock / ngenf / ngenf news

NGENF News and Press, NervGen Pharma Corp From 09/05/23

Stock Information
Company Name: NervGen Pharma Corp
Stock Symbol: NGENF
Market: OTC
Website: nervgen.com
Menu
NGENF NGENF Quote NGENF Short NGENF News NGENF Articles NGENF Message Board
Get NGENF Alerts

News, Short Squeeze, Breakout and More Instantly...
NGENF - NervGen Pharma to Present on Its Drug Candidate NVG-291 and Spinal Cord Injury at the H.C. Wainwright 25th Annual Global Investment Conference

Vancouver, British Columbia--(Newsfile Corp. - September 5, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that President & CEO, Mike Kelly, w...
NGENF - NervGen Pharma to Present on its Drug Candidate NVG-291 and Spinal Cord Injury at Investor Conference

Vancouver, British Columbia--(Newsfile Corp. - August 22, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that members of its management team will ...

NGENF - NervGen Pharma Reports Q2 2023 Financial Results and Operational Updates

Landmark Phase 1a/2b clinical trial of NVG-291 proceeds with recruitment of individuals with spinal cord injury; results expected in mid-2024 Seasoned life sciences executive, Mike Kelly, appointed President & CEO Awarded grant of up to US$3.18 million from Wings for Life to suppor...

NGENF - NervGen Pharma to Proceed with Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury Having Completed FDA Review and Received IRB Approval

Recruitment of individuals with spinal cord injury (SCI) initiated at Shirley Ryan AbilityLab in Chicago Chronic SCI cohort results expected in mid-2024 and subacute SCI cohort results in late 2024/early 2025 Vancouver, British Columbia--(Newsfile Corp. - August 8, 2023) - NervGen Pharma...
NGENF - NervGen Pharma to Receive More than US$3 Million from Wings for Life to Support Upcoming Clinical Study in Spinal Cord Injury

Vancouver, British Columbia--(Newsfile Corp. - June 27, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that it has be...

NGENF - Life Science Investor Forum: Presentations Now Available for Online Viewing

NEW YORK, June 23, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from Life Science Investor Forum, held on June 22 nd are now available for online viewing. REGISTER NOW AT : https://...

NGENF - NervGen Pharma to Present at Upcoming Investor Conferences

Vancouver, British Columbia--(Newsfile Corp. - June 20, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that members o...
NGENF - Life Science Investor Forum Agenda Announced for June 22nd

NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Science Investor Forum. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGIST...

NGENF - NervGen Pharma Extends the Expiry Date of Certain Stock Options

Vancouver, British Columbia--(Newsfile Corp. - June 2, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced a two-year extension ...

NGENF - NervGen Pharma GAAP EPS of -$0.08

2023-05-15 12:27:35 ET NervGen Pharma press release ( OTCQX:NGENF ): Q1 GAAP EPS of -$0.08. For further details see: NervGen Pharma GAAP EPS of -$0.08
Previous 10 Next 10